Key congressmen, John Dingell, chairman of the Committee on Energy and Commerce, and Bart Stupak, chairman of the Subcommittee on Oversight and Investigations, are looking at changes in law that will prohibit the marketing of any drug from a plant that has not been properly inspected.
Committee on Energy and Commerce
Friday, 22 February 2008
Call for inspections law change
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment